1
Clinical Trials associated with PF-07940367A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS
The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream.
This study is seeking participants who are:
- Healthy male or female participants aged 18 years or older.
All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367.
The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given.
Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.
100 Clinical Results associated with PF-07940367
100 Translational Medicine associated with PF-07940367
100 Patents (Medical) associated with PF-07940367
100 Deals associated with PF-07940367